What type of infection does micafungin primarily cover?

Micafungin is an echinocandin antifungal agent that is primarily used to treat invasive candidiasis. This type of infection is caused by Candida species, which can lead to serious systemic infections, particularly in immunocompromised patients. Micafungin works by inhibiting the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, ultimately leading to cell lysis and death. It is particularly effective against various Candida spp., including those that have shown resistance to other antifungal treatments.

Invasive candidiasis can occur in patients with central venous catheters, neutropenia, or other conditions that compromise the immune system. The effectiveness of micafungin in treating these infections makes it a critical choice in the management of serious fungal infections.

The other options, while related to fungal infections, do not correctly represent the primary application of micafungin. Dermatophyte infections are typically treated with azoles or allylamines, cryptococcal infections are more commonly managed with amphotericin B and flucytosine, and Aspergillus infections usually require the use of voriconazole or other specific agents. Therefore, the primary coverage of micafungin is